7 March 2025

Dr. Jack Cush reviews the news, journal reports and regulatory actions from the past week on RheumNow.com

Normalizing Serologies Enhances Remission in SLE Analysis of five phase III belimumab (BEL) trials reveals that normal

Tweet Author

Tweet Content

Normalizing Serologies Enhances Remission in SLE Analysis of five phase III belimumab (BEL) trials reveals that normalizing serologies affords protection against severe and renal SLE flares, supporting the concept of treat-to-target to minimize risk in SLE.… https://t.co/eW9EUyvts7 https://t.co/OdM0WkLtjd

Intraarticular Steroids in OA Lowers Need for Pain Meds Is it possible that intra-articular corticosteroid injections

Tweet Author

RheumNow

Tweet Content

Intraarticular Steroids in OA Lowers Need for Pain Meds Is it possible that intra-articular corticosteroid injections for osteoarthritis might affect the use of opioids? https://t.co/pw6vWbFRQx https://t.co/5KrB9uJv7M

Links

Intraarticular Steroids in OA Lowers Need for Pain Meds | RheumNow https://buff.ly/ySX0eGm

6 March 2025

MMWR: Idiopathic Pulmonary Fibrosis Mortality in the United States

Idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by scarring and worsening lung function, has a poor prognosis. An estimated 21% of IPF deaths might be attributable to occupational exposures.

Genentech announced that FDA has accepted a Supplemental Biologics License Application for obinutuzumab (anti-CD20 mAb;

Tweet Author

RheumNow

Tweet Content

Genentech announced that FDA has accepted a Supplemental Biologics License Application for obinutuzumab (anti-CD20 mAb; Gazyva) for the Treatment of Lupus Nephritis based on positive results from Phase III REGENCY study. FDA decision by October 2025 https://t.co/Mx3YDUfkMg https://t.co/MTBZo1TCrK

Links

Genentech: Press Releases | Tuesday, Mar 4, 2025 https://buff.ly/e2Pafxz

6 March 2025

ED Utilization by Psoriatic and Spondyloarthritis Patients

A cohort analysis of ambulatory emergency department (ED) utilization by patients with psoriatic arthritis (PsA) and radiographic axial spondyloarthritis (r-axSpA) demonstrated significant use for less urgent and nonurgent health issues, particularly in rural settings.

A study of administrative datasets from Alberta, Canada (2007-2018) assessed ED visit frequency, timing, triage acuity, diagnoses, and disposition for PsA and r-axSpA patients.

Sleep disturbance increases disability progression - Prospective cohort data from from 70K Nurses’ Health Study w/ 392

Tweet Author

RheumNow

Tweet Content

Sleep disturbance increases disability progression - Prospective cohort data from from 70K Nurses’ Health Study w/ 392 having MS, 7,302 DM, & 25K OA. Having Sleep apnea or disturbances signif incr disability in OA & DM (OR~1.4) as was excessive daytime sleepiness… https://t.co/5PP18gqDqi https://t.co/u1HFOstv8W

FDA grants priority reviews to: - Nicalizumab (J&J; FcRn antibody) for use in Myasthenia gravis. - Upadacitinib (Ab

Tweet Author

RheumNow

Tweet Content

FDA grants priority reviews to: - Nicalizumab (J&J; FcRn antibody) for use in Myasthenia gravis. - Upadacitinib (AbbVie; JAK inhib) for use in GCA - Namistat (BI: PDE4B inhib) for use in Idiopathic pulmonary fibrosis - Inalizumab (Hansen; anti-CD19) for use in IG4 rel Dz -… https://t.co/dsg9vZASrk https://t.co/8t2USASmm8

5 March 2025

A Review of Relapsing Polychondritis

A current review in the Journal of Thoracic Disease on relapsing polychondritis (RP), suggests that while this rare disorder may have an uncertain pathogenesis, its diagnosis and therapeutical management has improved.

This review focuses on key features, with damage to auricular or nasal cartilage, and tracheobronchial and cardiac involvement that can be severe, and life threatening.

SOCS1 Insufficiency - a Rare Inborn Error of Immunity Lancet Rheumatology has published a population study of the rare

Tweet Author

RheumNow

Tweet Content

SOCS1 Insufficiency - a Rare Inborn Error of Immunity Lancet Rheumatology has published a population study of the rare suppressor of cytokine signalling 1 (SOCS1) insufficiency - an inborn error of immunity affecting the negative regulation of cytokine and growth factor… https://t.co/I0muoIk5GL https://t.co/jbcuAZivci

Topics

Normalizing Serologies Enhances Remission in SLE Analysis of five phase III belimumab (BEL) trials reveals that normal

Intraarticular Steroids in OA Lowers Need for Pain Meds Is it possible that intra-articular corticosteroid injections

Genentech announced that FDA has accepted a Supplemental Biologics License Application for obinutuzumab (anti-CD20 mAb;

Sleep disturbance increases disability progression - Prospective cohort data from from 70K Nurses’ Health Study w/ 392

FDA grants priority reviews to: - Nicalizumab (J&J; FcRn antibody) for use in Myasthenia gravis. - Upadacitinib (Ab

SOCS1 Insufficiency - a Rare Inborn Error of Immunity Lancet Rheumatology has published a population study of the rare

Do you get our email newsletter?